Search

Your search keyword '"Tamori, Akihiro"' showing total 933 results

Search Constraints

Start Over You searched for: Author "Tamori, Akihiro" Remove constraint Author: "Tamori, Akihiro"
933 results on '"Tamori, Akihiro"'

Search Results

1. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study

2. Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma

5. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis

8. Soluble Immune Checkpoint Protein CD27 Is a Novel Prognostic Biomarker of Hepatocellular Carcinoma Development in Hepatitis C Virus–Sustained Virological Response Patients

10. Analysis of Carcinogenic Involvement of MicroRNA Pattern in Peripheral Non-Cancerous Tissues and Chronic Viral Liver Injury.

11. Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study

12. Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response

14. Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients

18. Importance of HBsAg recognition by HLA molecules as revealed by responsiveness to different hepatitis B vaccines

20. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis

22. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium

25. Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial

33. Risk factors for liver‐related and non‐liver‐related mortality following a sustained virological response after direct‐acting antiviral treatment for hepatitis C virus infection in a real‐world cohort

36. Cancer cells produce liver metastasis via gap formation in sinusoidal endothelial cells through proinflammatory paracrine mechanisms

37. Suppression of intrahepatic cholangiocarcinoma cell growth by SKI via upregulation of the CDK inhibitor p21

38. Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma

39. Sofosbuvir–velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan

42. Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma

43. 328: REAL-WORLD TREATMENT OUTCOME WITH PROTEASE INHIBITOR (PI) VS NON-PI DIRECT ACTING ANTIVIRALS (DAAS) IN DECOMPENSATED HCV CIRRHOSIS: A REAL-C STUDY

45. Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C

46. Direct‐acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment

48. Postoperative direct‐acting antiviral treatment after liver resection in patients with hepatitis C virus‐related hepatocellular carcinoma

49. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C

Catalog

Books, media, physical & digital resources